Full Name
Ross Andrew Soo
(not current staff)
Variants
Ross, S.
Soo, R.
Soo, R.-A.
Soo, R.A.
Soo, Ross
 
 
 
Email
csiras@nus.edu.sg
 

Publications

Results 1-20 of 91 (Search time: 0.012 seconds).

Issue DateTitleAuthor(s)
1Apr-2012A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancerNg, K.P.; Hillmer, A.M.; Chuah, C.T.H.; Juan, W.C.; Ko, T.K. ; Teo, A.S.M.; Ariyaratne, P.N.; Takahashi, N.; Sawada, K.; Fei, Y.; Soh, S.; Lee, W.H.; Huang, J.W.J.; Allen Jr., J.C.; Woo, X.Y.; Nagarajan, N.; Kumar, V.; Thalamuthu, A.; Poh, W.T.; Ang, A.L.; Mya, H.T.; How, G.F.; Yang, L.Y.; Koh, L.P.; Chowbay, B.; Chang, C.-T.; Nadarajan, V.S.; Chng, W.J.; Than, H.; Lim, L.C.; Goh, Y.T.; Zhang, S.; Poh, D.; Tan, P. ; Seet, J.-E.; Ang, M.-K.; Chau, N.-M.; Ng, Q.-S.; Tan, D.S.W.; Soda, M.; Isobe, K.; Nöthen, M.M.; Wong, T.Y. ; Shahab, A.; Ruan, X.; Cacheux-Rataboul, V.; Sung, W.-K.; Tan, E.H.; Yatabe, Y.; Mano, H.; Soo, R.A. ; Chin, T.M. ; Lim, W.-T.; Ruan, Y. ; Ong, S.T.
225-Mar-2020A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinomaKong, Li Ren ; Salleh, Nur Afiqah Binte Mohamed ; Ong, Richard Weijie; Tan, Tuan Zea ; Syn, Nicholas L; Goh, Robby Miguel; Fhu, Chee Wei ; Tan, Daniel SW ; Iyer, N Gopalakrishna ; Kannan, Srinivasaraghavan; Verma, Chandra S ; Lim, Yaw Chyn ; Soo, Ross ; Ho, Jingshan ; Huang, Yiqing; Lim, Joline SJ ; Yan, Benedict Junrong; Nga, Min En ; Lim, Seng Gee ; Koeffler, H Phillip ; Lee, Soo Chin ; Kappei, Dennis ; Hung, Huynh The ; Goh, Boon Cher 
3Nov-2011A comparative study of dynamic contrast-enhanced MRI parameters as biomarkers for anti-angiogenic drug therapyKoh, T.S.; Thng, C.H.; Hartono, S.; Tai, B.C. ; Rumpel, H.; Ong, A.B.; Sukri, N.; Soo, R.A. ; Wong, C.I.; Low, A.S.C.; Humerickhouse, R.A.; Goh, B.C.
42020A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East AsiansPeng, S.; Ying, A.F. ; Tai, B.C. ; Soo, R.A. 
5Apr-2008A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cellsMa, B.; Goh, B.C.; Tan, E.H.; Lam, K.C.; Soo, R. ; Leong, S.S.; Wang, L.Z. ; Mo, F.; Chan, A.T.C.; Zee, B.; Mok, T.
6Jul-2006A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancerSoo, R.A. ; Wang, L.Z. ; Tham, L.S.; Yong, W.P. ; Boyer, M.; Lim, H.L.; Lee, H.S.; Millward, M.; Liang, S.; Beale, P.; Lee, S.C. ; Goh, B.C.
71-Mar-2022A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignanciesHo, Jingshan ; Heong, Valerie; Yong, Wei Peng ; Soo, Ross ; Chee, Cheng Ean ; Wong, Andrea ; Sundar, Raghav; Thian, Yee Liang ; Gopinathan, Anil ; Pang, Mei Yan; Koe, Priscillia; Jeraj, Santhiay Nathan; Soe, Phyu Pyar; Soe, Mu Yar; Tang, Tiffany ; Ng, Matthew CH; Tai, David WM ; Tan, Tira JY ; Xu, Hongmei; Chang, Hua; Landesman, Yosef; Shah, Jatin ; Shacham, Sharon; Lee, Soo Chin ; Tan, Daniel SW ; Goh, Boon Cher ; Tan, David SP 
8Jul-2008A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancersYong, W.-P. ; Wang, L.-Z. ; Tham, L.-S.; Wong, C.-I.; Lee, S.-C. ; Soo, R. ; Sukri, N.; Lee, H.-S.; Goh, B.-C.
915-Apr-2023A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological MalignanciesChee, Cheng E ; Ooi, Melissa ; Lee, Soo-Chin ; Sundar, Raghav ; Heong, Valerie; Yong, Wei-Peng ; Ng, Chin Hin ; Wong, Andrea; Lim, Joline SJ ; Tan, David SP ; Soo, Ross ; Tan, Joshua TC; Yang, Song; Thura, Min; Al-Aidaroos, Abdul Qader; Chng, Wee Joo ; Zeng, Qi ; Goh, Boon-Cher 
102020A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumoursAng, Y.L.E.; Ho, G.F.; Soo, R.A. ; Sundar, R. ; Tan, S.H.; Yong, W.P. ; Ow, S.G.W. ; Lim, J.S.J. ; Chong, W.Q.; Soe, P.P.; Tai, B.C. ; Wang, L. ; Goh, B.C. ; Lee, S.-C. 
112017A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancerSoh, S.X; Siddiqui, F.J ; Allen, J.C ; Kim, G.W; Lee, J.C; Yatabe, Y; Soda, M; Mano, H; Soo, R.A ; Chin, T.-M ; Ebi, H; Yano, S; Matsuo, K; Niu, X; Lu, S; Isobe, K; Lee, J.-H; Yang, J.C; Zhao, M; Zhou, C; Lee, J.-K; Lee, S.-H; Lee, J.Y; Ahn, M.-J; Tan, T.J; Tan, D.S ; Tan, E.-H; Ong, S.T ; Lim, W.-T 
122017Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysisKoh K.X.; Tan G.H.; Low S.H.H. ; Omar M.F.M. ; Han M.J.; Iacopetta B.; Soo R. ; Beloueche-Babari M.; Bhattacharya B. ; Soong R. 
13Oct-2012Activation of IL-6R/JAK1/STAT3 signaling induces De Novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutationKim, S.M.; Kwon, O.-J.; Hong, Y.K.; Kim, J.H.; Solca, F.; Ha, S.-J.; Soo, R.A. ; Christensen, J.G.; Lee, J.H.; Cho, B.C.
142016Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its developmentWang, L ; Khoa Phan, D.D; Zhang, J; Ong, P.-S ; Thuya, W.L ; Soo, R.A ; Wong, A.L.-A ; Yong, W.P ; Lee, S.C ; Ho, P.C.-L ; Sethi, G ; Goh, B.C 
15Oct-2013Can population differences in chemotherapy outcomes be inferred from differences in pharmacogenetic frequenciesLoh, M. ; Chua, D.; Yao, Y.; Soo, R.A. ; Garrett, K.; Zeps, N.; Platell, C.; Minamoto, T.; Kawakami, K.; Iacopetta, B.; Soong, R. 
1616-Feb-2023Clinical outcome and prognostic factors for Asian patients in Phase I clinical trialsLoh, Jerold; Wu, Jiaxuan; Chieng, Jenny; Chan, Aurora; Yong, Wei-Peng ; Sundar, Raghav ; Lee, Soo-Chin ; Wong, Andrea; Lim, Joline SJ ; Tan, David SP ; Soo, Ross ; Goh, Boon-Cher ; Tai, Bee-Choo ; Chee, Cheng E 
17May-2009Clinical pharmacology and pharmacogenetics of gemcitabineWong, A.; Soo, R.A. ; Yong, W.-P. ; Innocenti, F.
182017Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1Wang, L ; Chan, C.E.L; Wong, A.L.-A ; Wong, F.C; Lim, S.W ; Chinnathambi, A; Alharbi, S.A; Lee, L.S.-U ; Soo, R ; Yong, W.P ; Lee, S.C ; Ho, P.C.-L ; Sethi, G ; Goh, B.C 
1920-May-2020Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma (NPC).Walsh, Robert John; Nickles, Emily Pauline ; Li, Yating ; Dharmadhikari, Bhushan ; Koh, Mickey; Ho, Liam Pock ; Chan, Marieta; Koh, Liang Piu ; Poon, Michelle Li Mei; Tan, Lip Kun ; Huang, Yiqing; Ang, Yvonne Li'en; Chong, Wan Qin; Asokumaran, Yugarajah; Loh, Kwok Seng ; Soo, Ross A ; Lim, Chwee Ming ; Schwarz, Herbert ; Goh, Boon Cher 
2018-Oct-2021Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefitNickles, Emily ; Dharmadhikari, Bhushan ; Li, Yating ; Walsh, Robert J; Koh, Liang Piu ; Poon, Michelle ; Tan, Lip Kun ; Wang, Ling-Zhi; Ang, Yvonne; Asokumaran, Yugarajah; Chong, Wan Qin; Huang, Yiqing; Loh, Kwok Seng ; Tay, Joshua ; Soo, Ross ; Koh, Mickey; Ho, Liam Pock ; Chan, Marieta; Niam, Madelaine; Soh, Melissa; Luah, Yen Hoon ; Lim, Chwee Ming ; Kaliaperumal, Nivashini; Au, Veonice B; Talib, Najwa Binte Said Nasir; Sng, Reina ; Connolly, John E ; Goh, Boon Cher ; Schwarz, Herbert